AGTR1 and Marfan syndrome: It is a widely used, orally administered FDA-approvedmedication for hypertension with an excellent safety profile.15 Although itsprimary target is the angiotensin II type 1 receptor (AT1), it is also known toindirectly attenuate canonical TGF-beta signaling in the vasculature.16Additionally, its vascular modifying effects are also the current focus of aphase 3 clinical trial (ClinicalTrials.gov identifier: NCT00763893; Efficacy ofLosartan on Aortic Dilatation in Patients with Marfan Syndrome).